Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.

ABSTRACT:

Background

Signaling through mTOR and somatostatin pathway is implicated in thyroid cancer development.

Method

We evaluated everolimus, an mTOR inhibitor and pasireotide, a multi receptor somatostatin analogue as potential therapy of thyroid cancer focusing on the in vitro and in vivo efficacy, as well as possible mechanism to explain any observed interaction.

Results

Both everolimus and pasireotide inhibit the growth of thyroid cancer cell lines in vitro with varied efficacy that correlates with tumor origin and somatostatin receptor (SSTR) expression profile of the cell lines. In vitro activity of everolimus show positive correlation with the expression of SSTR types 1, 4 and 5 (CC: 0.9; 0.85, 0.87) while pasireotide activity show negative correlation with SSTR2 (CC

SUBMITTER: Owonikoko TK 

PROVIDER: S-EPMC6390992 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature